GlassScriptPhysician profile
Catherine L Midyett
NPI 1588965156
$12,539.93
in general payments reported to CMS, 2019-2025
37 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,590 · 2022: $2,917 · 2023: $2,486 · 2024: $2,138 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,929 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,928.52 |
| Education | $104.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,256.86 | 2021-2025 | Enbrel, Krystexxa, Otezla |
| Abbvie INC. | $2,288.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,054.49 | 2021-2025 | |
| Ucb, INC. | $863.68 | 2021-2025 | Bimzelx, Cimzia |
| Bayer Healthcare Pharmaceuticals INC. | $793.42 | 2022-2025 | |
| Pfizer INC. | $713.45 | 2021-2025 | |
| Janssen Biotech, INC. | $525.66 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $513.80 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $365.28 | 2021-2024 | Taltz, Jardiance |
| Astrazeneca Pharmaceuticals LP | $292.72 | 2021-2025 | Saphnelo, Evusheld |
| Genentech USA, INC. | $253.64 | 2021-2023 | Actemra |
| Cumberland Pharmaceuticals, INC. | $167.96 | 2021-2022 | |
| Genzyme Corporation | $160.14 | 2021-2025 | |
| Novo Nordisk INC | $151.30 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.27 | 2023-2025 | Cyltezo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $106.72 | 2023-2025 | Dexcom G6 Transmitter |
| Ani Pharmaceuticals, INC. | $103.89 | 2022-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $96.73 | 2022-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $96.38 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $95.70 | 2021-2024 | Gvoke Hypopen |
| Mallinckrodt Hospital Products INC. | $92.80 | 2021-2024 | Acthar |
| Sandoz INC. | $66.23 | 2023-2025 | Hyrimoz |
| United Therapeutics Corporation | $54.14 | 2024-2025 | Tyvaso, Tyvaso |
| Alexion Pharmaceuticals, INC. | $41.70 | 2021-2024 | Strensiq |
| Medtronic, INC. | $38.19 | 2021 | |
| Corcept Therapeutics | $35.11 | 2023-2025 | Korlym |
| Kyowa Kirin, INC. | $25.68 | 2024 | Crysvita |
| Sequel Med Tech, LLC | $22.88 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $22.08 | 2021 | |
| Cequr Corporation | $21.00 | 2025 | Cequr Simplicity |
| Fresenius Kabi USA, LLC | $18.03 | 2024 | Idacio |
| Insulet Corporation | $16.98 | 2025 | Omnipod |
| Pacira Therapeutics, INC. | $15.82 | 2021 | |
| Aurinia Pharma U.S., INC. | $15.57 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.41 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.58 | 2024 | |
| Organon LLC | $11.88 | 2023 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Midyett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.